Iran develops smart personalized vaccine for lung cancer

Pars Today – An associate professor at Tehran University of Medical Sciences has announced the development of a personalized, smart vaccine against lung cancer.

Lung cancer remains one of the deadliest forms of cancer worldwide, and research into innovative and effective treatments is continually advancing. In this effort, Dr. Mohammad Hossein Yazdi, Director of the Biotechnology Research Center at Tehran University of Medical Sciences and Associate Professor at Iran’s Faculty of Pharmacy, has made significant strides in developing personalized, smart vaccines targeting lung cancer.

According to Pars Today, Dr. Yazdi, discussing the development of the Iranian smart vaccine for lung cancer, said: “This innovative vaccine is designed using mRNA technology and AI-based predictive algorithms, allowing precise personalization based on each patient’s tumor genetics.”

He added that this approach could significantly shorten the research and development timeline and open new horizons in the treatment and prevention of lung cancer.

Yazdi believes that one of the vaccine’s most prominent strengths is its precise predictive capability. Unlike traditional vaccines, which rely on extensive trial and error, this smart vaccine uses patients’ tumor genetic data and advanced AI algorithms to identify the optimal vaccine candidate before entering clinical trials. This approach can accelerate the vaccine development process by up to 90%, reducing the design and preparation time to just two to three weeks.

He emphasized that vaccine personalization not only enables treatment for cancer patients but can also serve a preventive role for individuals at risk. This feature transforms the vaccine from a standard product into an innovative tool in precision medicine, promising a major breakthrough in lung cancer treatment.